Hepion Pharmaceuticals (HEPA)
(Real Time Quote from BATS)
$0.81 USD
-0.21 (-20.59%)
Updated Jul 22, 2024 02:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HEPA 0.81 -0.21(-20.59%)
Will HEPA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HEPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HEPA
Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
HEPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HEPA
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring
Hepion Pharmaceuticals enters merger agreement with Pharma Two B
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024
Biotech Alert: Searches spiking for these stocks today